Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
Background: Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that prop...
Main Authors: | Ikaro Breder, Jessica Cunha Breder, Isabella Bonilha, Daniel B. Munhoz, Sheila T. Kimura Medorima, Daniela C. Oliveira, Helison R. do Carmo, Camila Moreira, Anatol Kontush, Francesca Zimetti, Ilaria Zanotti, Luiz Sergio F. Carvalho, Wilson Nadruz, Elza Muscelli, Thiago Quinaglia, Andrei C. Sposito |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | Therapeutic Advances in Chronic Disease |
Online Access: | https://doi.org/10.1177/2040622320959248 |
Similar Items
-
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
by: Riobaldo M. R. Cintra, et al.
Published: (2019-07-01) -
Cardiovascular autonomic neuropathy in type 2 diabetic patients
by: Ikaro Soares Santos Breder, et al. -
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
by: Vaneza Lira W. Wolf, et al.
Published: (2021-06-01) -
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
by: Andrei C. Sposito, et al.
Published: (2021-03-01) -
Analytic charged BHs in f(R) gravity
by: G.G.L. Nashed, et al.
Published: (2021-09-01)